PET/CT Imaging in Gynecologic Malignancies Other than Ovarian and Cervical Cancer

摘要

Recent advances in PET and combined PET/ computed tomography (CT) has increased its usefulness in oncologic imaging. The ability of PET to detect malignancy relies on the metabolic activity of the tumors that incorporate the PET radiopharmaceutical. When combined with CT, accurate anatomic localization of the metabolic abnormality is also possible. Currently PET with fluorine 18 [~(18)F]flu6rodeoxyglucose (FDG) is the most commonly used agent for the diagnosis and staging of gynecologic malignancies. Newer agents such as [16a-~(18)F]fluoro-17p-estradiol (FES), a radiolabeled compound of the most bioactive type of estrogen, are being evaluated for detection of tumors that may be characterized as estrogen receptor (ER)-positive. ~(18)F-labeled radioactive isotopes decay by positron emission and their detection indicates the presence of metabolically active sites of potential malignant origin.